At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
Dapagliflozindrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients.
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin for Diabetes Mellitus, Type 2 and Skeletal Muscle Insulin Sensitivity. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartMar 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedNov 9, 2017
Enrollment StartMar 5, 2018
Primary CompletionNov 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.6 years ago
Interventions
Dapagliflozindrug
The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2. The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2.